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Even with the recent optimization of haploidentical stem cell transplantation (SCT), its role for patients with
myelodysplastic syndrome (MDS) or acute myeloid leukemia evolving from MDS (sAML) should be validated.
We analyzed the outcomes of consecutive 60 patients with MDS or sAML who received T cellereplete
haploidentical SCT after reduced-intensity conditioning with ﬂudarabine, busulfan, and rabbit antithymocyte
globuline  800 cGy total body irradiation. Patients achieved a rapid neutrophil engraftment after a median of
12 days (range, 8 to 23) and an early immune reconstitutionwithout high incidences of acute graft-versus-host
disease (GVHD) II to IV and chronic GVHD (36.7% and 48.3%, respectively). After a median follow-up of 4 years,
incidence of relapse and nonrelapse mortality and rate of overall survival and disease-free survival was 34.8%,
23.3%, 46.8%, and 41.9%, respectively. In multivariate analysis, the disease status at peak was a signiﬁcant
predictor for relapse (lower-risk MDS versus higher-risk MDS or sAML; hazard ratio [HR], 5.69; 95% conﬁdence
interval [CI], 1.45 to 22.29; P¼ .013) and disease-free survival (HR, 4.44; 95% CI, 1.14 to 17.34; P¼ .032). Chronic
GVHDwas an additional signiﬁcant predictor for relapse (no versus yes; HR, 2.87; 95% CI, 1.03 to 7.51; P¼ .043).
Our T cellereplete haploidentical SCT may be a feasible option for patients with MDS and sAML without
conventional donors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (SCT) is the only
therapeutic option with curative potential for patients with
myelodysplastic syndrome (MDS), despite recent clinical
applications of novel agents, which carried considerable
response rates or survival beneﬁts [1]. Nevertheless, many
patients who are candidates for allogeneic SCT lack human
leukocyte antigen (HLA)-matched siblings (MSD) or unrelated
donors (URD). For thesepatients, haploidentical relateddonors
can be an attractive option because of almost universal and
immediate donor availability and the possibility of additional
donations for stem cell boost or cellular immunotherapy.edgments on page 348.
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ty for Blood and Marrow Transplantation.However, early studies on haploidentical SCT resulted
in unacceptably high incidences of graft rejection and
graft-versus-host disease (GVHD) [2-4]. To overcome these
bidirectional barriers ofHLA incompatibilities, Tcelledepleted
haploidentical SCT was attempted with the infusion of
megadose peripheral blood (PB) stem cell grafts after
intensive conditioning [5-7]. Although this strategy was
effective in reducing the incidences of graft rejection and
GVHD, the high infection-related mortality rate due to a
delayed immune reconstitution remained a challenge. An
alternative strategy was attempted using T cellereplete (TCR)
haploidentical SCTwith effectiveGVHDprophylaxis, including
antithymocyte globulin (ATG) or post-transplantation cyclo-
phosphamide, which showed favorable survival rates with
reduced infection-related mortality [8-13].
Even with the progressive optimization of the hap-
loidentical SCT in various hematological diseases, its role for
patientswithMDS and acutemyeloid leukemia evolving from
MDS (sAML) has not been fully investigated yet. Recently,
S.-H. Shin et al. / Biol Blood Marrow Transplant 21 (2015) 342e349 343Chen et al. reported the outcomes of TCR haploidentical
SCT with a myeloablative conditioning (MAC) regimen in
patients with advanced MDS or sAML, which showed a
considerably high disease-free survival (DFS) rate (64.6% at
2 years) with sustained engraftment and an acceptable
incidence of GVHD [9]. However, TCR haploidentical SCT
using a reduced-intensity conditioning (RIC) regimen has
never been addressed focusing on patients with MDS. To
address these issues, we analyzed the relative long-term
outcomes of consecutive patients with MDS or sAML who
received TCR haploidentical SCT using RIC regimens at 2
transplantation centers in Korea.
METHODS
Patients and Pretransplantation Therapeutic Strategies
We analyzed the outcomes of 60 consecutive patients who received
haploidentical SCT for MDS or sAML between December 2004 and February
2012. Thirty-seven patients (61.7%), including 15 in our previously published
report [12], were from the Asan Medical Center (AMC) and 23 (38.3%) were
from the Catholic Blood and Marrow Transplantation Center (CBMTC). This
retrospective study was approved by institutional review boards of each
institution.
We considered immediate allogeneic SCT for patients with higher-risk
MDS with an optional pretransplantation hypomethylating treatment
(HMT). Patients with lower-risk MDS who had poor prognostic features
(PPF) [14,15] and/or signs of progression or sustained profound cytopenia
(deﬁned as a neutrophil count<.5109/L and/or platelet count<20109/L)
after HMT were considered candidates for allogeneic SCT. All patients who
experienced progression to sAMLwere considered for allogeneic SCTwith or
without preceding anthracycline-based intensive chemotherapy (ICTx) for
remission induction [16,17]. However, patients with organ dysfunctions
and/or poor performance status who were unsuitable for allogeneic SCT
using RIC were excluded. Haploidentical related donorswere searchedwhen
the patients had no MSD or suitable (at least 7 of 8 allele matched) URD by
screening for HLA-A, -B, -C, and -DRB1 alleleswith all potential donors, using
the high-resolution (DNA sequencing) molecular typing method.
Transplantation Procedures
The AMC used a conditioning regimen consisting of ﬂudarabine
(180 mg/m2), i.v. busulfan (6.4 mg/kg), and rabbit ATG (12 mg/kg), of which
the dose was reduced to 9 mg/kg from September 2009 as reported
previously [12]. The CBMTC used a similar regimen consisting of ﬂudarabine
(150 mg/m2), i.v. busulfan (6.4 mg/kg), and rabbit ATG (10 mg/kg), but
fractionated total body irradiation (TBI; 800 cGy) was added. Granulocyte
colonyestimulating factor (G-CSF)emobilized PB stem cells were infused
without ex vivo T cell depletion. Calcineurin inhibitors, such as cyclosporine
(at AMC) or tacrolimus (at CBMTC), plus short-course methotrexate
were used for GVHD prophylaxis. All patients received prophylactic oral
quinolone antibiotics and an antifungal agent consisting of oral triazole or
i.v. micafungin (50 mg per day) from the beginning of conditioning. G-CSF
was administered from day 5 (at AMC) or 7 (at CBMTC) at a dose of 5 mg/kg
to neutrophil recovery. All prophylactic agents and G-CSF were dis-
continued until the absolute neutrophil count was recovered to 3  109/L.
For cytomegalovirus (CMV) prophylaxis, i.v. high-dose acyclovir (10mg/kg 3
times per day) was administered from the start of conditioning. According
to the guidelines of 2 institutions [18,19], a preemptive therapy was
conducted with gancyclovir (5 mg/kg/day twice per day) or foscarnet (60
mg/kg twice per day) to prevent CMV disease in patients who experienced
CMV reactivation. The post-transplantation immune reconstitution was
estimated by counting CD4þ Tcells, CD8þ Tcells, and natural killer (NK) cells
in PB at 1, 3, 6, 9, and 12 months after transplantation.
Deﬁnitions
MDS was diagnosed by the French-American-British criteria [20] and
categorized according to the World Health Organization classiﬁcation [21].
The disease risk was evaluated and classiﬁed by the International Prognostic
Scoring System (IPSS) [22] as follows: low or intermediate-1 as lower-risk
MDS and intermediate-2 or high as higher-risk MDS. For analytic purposes,
chronic myelomonocytic leukemia and myelodysplastic/myeloproliferative
neoplasm were also assessed by the same criteria. In addition to the risk
at diagnosis, the disease risk at peak was assessed and classiﬁed by the
highest IPSS score during the disease course before transplantation. The
bone marrow (BM) blast count and the cytogenetic risk by IPSS were also
evaluated within 1 month before conditioning and were used to evaluate
the disease status at transplantation. The response to pretransplantationHMT was assessed according to the modiﬁed International Working
Group 2006 response criteria [23]. Pretransplantation treatment failure
was deﬁned as not achieving sustained responses after HMT or ICTx.
Neutrophil and platelet engraftment were deﬁned as an absolute neutrophil
count .5  109/L on the ﬁrst 3 consecutive days and platelets 20 109/L
without transfusion support on the ﬁrst 7 consecutive days, respectively.
Secondary graft failurewas deﬁned as absolute neutrophil count <.5  109/L
without recovery after initial engraftment. Acute and chronic GVHD were
evaluated by the criteria proposed by Przepiorka et al. and National
Institutes of Health, respectively [24,25]. In addition, the severity of chronic
GVHD was represented using global grading system after involved organ-
speciﬁc scoring as described in the criteria. Other transplantation-related
complications, including sinusoidal obstruction syndrome (SOS) and
hemorrhagic cystitis, were diagnosed and classiﬁed by previously
published criteria [26,27]. The causes of deathwere categorized according to
the scheme proposed by Copelan et al. [28]. GVHD-speciﬁc mortality was
deﬁned as death due to GVHD complications without relapse from the onset
of GVHD.
Statistical Analysis
The primary objective of this study was to analyze the outcomes of
patients with MDS or sAML who received haploidentical SCT. Major
endpoints were relapse, nonrelapse mortality (NRM), overall survival (OS),
and DFS. Continuous variables were summarized as median and range,
whereas categorical variables were described by counts and relative
frequencies. Comparisons of the clinical and transplantation-related
characteristics were carried out using the chi-square test or Fisher’s exact
test for categorical variables and the independent 2 sample t-test or
Mann-Whitney U-test for continuous variables. Curves for OS and DFS were
plotted using the Kaplan-Meier estimate and compared using the log-rank
test. In addition, curves for the cumulative incidence of relapse and NRM
were plotted using the estimates of cumulative incidence and compared
using the Gray’s test. The prognostic signiﬁcance of factors affecting OS and
DFS were determined using the Cox proportional hazards ratio (HR) model,
whereas factors affecting the cumulative incidence of relapse and NRMwere
determined using the semiparametric proportional hazards model for the
subdistribution of competing risk analysis. Acute GVHD grade II to IV
and chronic GVHD were planned to be introduced in the ﬁnal models of
multivariate analysis for each outcome as time-dependent covariates [29].
Factors were considered signiﬁcant if they had an associated P < .05 as
determined by the likelihood ratio test, using 2-tailed signiﬁcance testing.
Statistical analyses were performed with SAS (version 9.3; SAS Institute,
Cary, NC) in April 2014.
RESULTS
Baseline Clinical and Transplantation-Related
Characteristics
The median age of patients at transplantation was 48
(range, 19 to 69) years. When we categorized the patients
regarding the disease risk at peak, 16 (26.7%) patients had
lower-risk MDS and 44 (73.3%) higher-risk MDS or sAML. Of
39 patients receiving HMT before transplantation, responses
were maintained in 12 patients and primary or secondary
treatment failure developed in 27 patients (8 [50%] in
lower-risk MDS and 19 [43.2%] in higher-risk MDS or sAML).
After an ICTx for the 17 patients with progression to sAML,
7 (41.2%) achieved a sustained marrow complete remission
(CR). There was no signiﬁcant difference in characteristics
according to each transplantation center, except more
4 loci HLA-mismatched donor-recipient pairs (87.0%
versus 59.5%; P ¼ .041) in patients of CBMTC. The median
infused mononuclear cell, CD34þ, and CD3þ cell counts
were 8.0  108/kg (range, .9 to 19.4), 6.0  106/kg (range, .5
to 21.5), and 44.9  107/kg (range, 3.1 to 103.1), respectively.
Other baseline clinical and transplantation-related charac-
teristics of our cohort patients are summarized in Table 1.
Engraftment and GVHD
All patients, except 3 (5.0%) patients who died within
28 days of transplantation, achieved neutrophil engraftment
a median of 12 days (range, 8 to 23; Table 2). PCR DNA
ﬁngerprinting of the short tandem repeats on the recipient
Table 2
Engraftment, Graft-versus-Host Disease, and Early Complications after
Transplantation
Outcomes Value
Neutrophil engraftment at day 28 95.0 (85.1-98.4)
Days, median (range) 12 (8-23)
Platelet engraftment at day 28 81.7 (68.9-89.6)
Days, median (range) 15 (6-132)
Secondary graft failure at 4 yr 3.5 (.6-11.0)
Virus-associated complications, n (%)
CMV reactivation 40 (66.7)
Herpes zoster 10 (16.7)
Hemorrhagic cystitis (grade  II) 11 (18.3)
Acute GVHD at day 100
Grade II-IV 36.7 (24.6-48.8)
Grade III-IV 16.7 (8.5-27.2)
Chronic GVHD at 4 yr
Mild 48.3 (35.0-60.4)
Moderate 36.7 (24.5-48.8)
Severe 21.7 (12.2-32.9)
GVHD-speciﬁc mortality at 4 yr 16.7 (6.6-30.6)
SOS, n (%) 5 (8.3)
Data presented are incidence, % (95% CI), unless otherwise indicated.
Table 1
Baseline Clinical and Transplantation-Related Characteristics
Characteristics Value
Baseline demographics
Age at transplantation, median (range), yr 48 (19-69)
Male/female 47 (78.3)/13 (21.7)
Disease characteristics at Dx.
WHO subtype
RA or RARS/MDS-U 10 (16.7)/2 (.3)
RCMD 19 (31.7)
RAEB-1/RAEB-2 14 (23.3)/10 (16.7)
MDS/MPN 3 (5.0)
CMML 1 (1.7)
Unknown 1 (1.7)
Cytogenetic risk
Good 34 (56.7)
Intermediate/poor 13 (21.7)/8 (13.3)
Unknown 5 (8.3)
Disease risk
Lower-risk MDS 41 (68.3)
Higher-risk MDS 19 (31.7)
Treatment before transplantation and disease characteristics at peak
Pretransplantation treatment
No treatment 12 (20.0)
HMT only 31 (51.7)
Intensive CTx only 9 (15.0)
HMT þ intensive CTx 8 (13.3)
Pretransplantation treatment outcome
Ongoing response for HMT 12 (30.8*)
HMT failure 26 (66.7*)
Intensive CTx failure 10 (58.8*)
Treatment failure 29 (48.3)
WHO subtype at peak
RA or RARS 5 (8.3)
RCMD 12 (20.0)
RAEB-1/RAEB-2 8 (13.3)/16 (26.7)
sAML 17 (28.3)
MDS/MPN 1 (1.7)
CMML 1 (1.7)
Disease risk at peak
Lower-risk MDS 16 (26.7)
Higher-risk MDS/sAML 27 (45.0)/17 (28.3)
Disease characteristics at transplantation
Cytogenetic risk
Good 32 (53.3)
Intermediate/poor 18 (30.0)/10 (16.7)
BM blast count, median (range), % 3.3 (0-89)
<5% 34 (56.7)
5% 26 (43.3)
Transplantation-related characteristics
Transplantation center
AMC 37 (61.7)
CBMTC 23 (38.3)
Interval from Dx., median (range), mo 13.1 (2.8-93.2)
<12 mo/12 mo 29 (48.3)/31 (51.7)
HCT-CI, median (range) 1 (0-6)
<3/3 51 (85.0)/9 (15.0)
Number of HLA disparity
1-3 loci 18 (30.0)
4 loci 42 (70.0)
Relation between donor and recipient
Mother 11 (18.3)
Sibling 20 (33.3)
Offspring 29 (48.3)
Donor/recipient sex discrepancy
Female to male 18 (30.0)
Others 42 (70.0)
Donor/recipient ABO match
Matched 39 (65.0)
Mismatched 21 (35.0)
Dx. indicates diagnosis; WHO, World Health Organization; RA, refractory
anemia; RARS, refractory anemia with ringed sideroblasts; MDS-U,
myelodysplastic syndrome unclassiﬁed; RCMD, refractory cytopenia with
multilineage dysplasia; RAEB, refractory anemia with excess blasts; MPN,
myeloproliferative neoplasm;CMML, chronicmyelomonocytic leukemia;CTx.,
chemotherapy;HCT-CI, hematopoietic cell transplantation-comorbidity index.
Data presented are n (%) unless otherwise indicated.
* The proportion of the patients who experienced response or failure for
those received respective treatment.
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(range, 98.5% to 100%) donor chimerism within 1 month of
transplantation. During the follow-up period, 50 (83.3%)
patients achieved platelet engraftment after a median of 15
days (range, 6 to 132; Table 2). Consequently, the cumulative
incidences of neutrophil and platelet engraftment at days 28
were 95.0% (95% conﬁdence interval [CI], 85.1 to 98.4) and
81.7% (95% CI, 68.9 to 89.6), respectively (Table 2). Patients
receiving a TBI-containing regimen showed signiﬁcantly
faster neutrophil (11.0 days versus 13.0 days; P < .001) and
platelet engraftment (13.0 days versus 22.5 days; P ¼ .011).
Secondary graft failure was only observed in 2 patients at 1.0
and 4.8 months after transplantation, with a cumulative
incidence at 4 years of 3.5% (95% CI, .6 to 11.0; Table 2).
At a median of 23.5 days (range, 9 to 91) after trans-
plantation, 22 patients experienced acute GVHD grade II
to IV. Of them, 12 (54.5%) patients had acute GVHD grade II
and 10 (45.5%) acute GVHD grades III and IV. The cumulative
incidences of acute GVHD grade II to IV and grade III and
IV at day 100 were 36.7% (95% CI, 24.6 to 48.8) and 16.7%
(95% CI, 8.5 to 27.2), respectively (Table 2). Chronic GVHD
occurred in 29 patients at a median of 3.7 months (range,
.8 to 20.1), with 9 (31.0%) experiencing moderate chronic
GVHD and 13 (44.8%) severe chronic GVHD. The cumulative
incidences of mild-to-severe, moderate-to-severe, and
severe chronic GVHD at 4 years were 48.3% (95% CI, 35.0 to
60.4), 36.7% (95% CI, 24.5 to 48.8), and 21.7% (95% CI, 12.2 to
32.9), respectively (Table 2). In addition, the cumulative
incidence of GVHD-speciﬁc mortality at 4 years was 16.7%
(95% CI, 6.6 to 30.6; Table 2).
Early Complications and Immune Reconstitution
Forty (66.7%) patients experienced at least one positive
CMV pp65 antigenemia or CMV DNA PCR assay at a median
of 35 days (range, 26 to 56 days) after transplantation
(Table 2) and preemptive treatment was required for
21 (35.0%) patients. CMV disease developed in 4 (6.7%) pa-
tients (CMV colitis in 3 and CMV gastritis in 1 patient). Other
early virus-associated complications, including herpes zoster
and hemorrhagic cystitis grade II to IV were observed in 10
(16.7%) and 11 (18.3%) patients, respectively (Table 2). In
addition, SOS developed in 5 (8.3%) patients (Table 2). No
patient died of these virus-associated complications or SOS.
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patients who survived at least 6months after transplantation
without relapse. Those data were available for 39, 38, 37, 15,
and 27 patients at 1, 3, 6, 9, and 12 months, respectively.
Among them, NK cells recovered most rapidly with a mean
count of 273  32/mL at 1 month after transplantation
(Figure 1A). In addition, the mean CD8þ T cell count was 949
 126/mL at 3 months after transplantation (Figure 1B).
However, CD4þ T cells recovered most slowly with a mean
count of 268  26/mL and 391  42/mL at 6 and 12 months
after transplantation, respectively (Figure 1C).
Relapse and NRM
Twelve (33.3%) patients experienced relapse at a median
of 7.6 (range, .5 to 37.6) months after transplantation. Among
them, 17 (85.0%) patients died of disease progression after
receiving conservative care only (n ¼ 6), ICTx (n ¼ 4),
low-dose cytarabine (n ¼ 2), donor lymphocyte infusion
(n ¼ 2), and second haploidentical SCT from another donor
(n ¼ 3), without achieving sustained response. Another
3 (15.0%) patients remained alive at last follow-up with
marrow CR after receiving azacytidine, donor lymphocyte
infusion after ICTx, and low-dose cytarabine, respectively.
The cumulative incidence of relapse at 4 years for all patients
was 34.8% (95% CI, 22.5% to 47.4%). It was signiﬁcantly
different according to the disease risk at peak (P ¼ .007;
Figure 2A) with 6.2% (95% CI, .4% to 25.7%) in patients with
lower-risk MDS and 46.4% (95% CI, 29.4% to 61.7%) in those
with higher-risk MDS or sAML. In univariate analysis, the age
at transplantation (48 years versus <48 years; P ¼ .047)
was an additional potential factor predicting the incidence
of relapse. Other baseline clinical or transplantation-related
factors, including transplantation center (AMC versus
CBMTC) and cytogenetic risk at transplantation (poor versus
good/intermediate), did not affect the incidence of relapse
(P> .100) (Supplementary Table S1). In multivariate analysis,
disease risk at peak (higher-risk MDS or sAML versus lower-
risk MDS; HR, 5.69; 95% CI, 1.45 to 22.29; P ¼ .013) and
chronic GVHD (no versus yes; HR, 2.78; 95% CI, 1.03 to 7.51;
P ¼ .043) were signiﬁcant factors affecting the incidence of
relapse (Table 3).
On the other hand, 14 (23.3%) patients died without
relapse at a median of 4.5 (range, .3 to 20.5) months after
transplantation. The primary causes of NRMwere as follows:
acute GVHD in 4, chronic GVHD in 2, infectious complica-
tions in 5, secondary graft failure in 1, cerebrovascular
hemorrhage in 1, and multi-organ failure in 1 patient. TheFigure 1. Immune reconstitution estimated by lymphocyte subsets (A) NK cell cou
 standard error.cumulative incidence of NRM at 4 years for all patients was
23.3% (95% CI, 13.5% to 34.7%). It was not signiﬁcantly
different according to the disease risk at peak (P ¼ .705;
Figure 2B) with 18.8% (95% CI, 4.3% to 41.0%) in patients with
lower-risk MDS and 25.0% (95% CI, 13.3% to 38.6%) in those
with higher-risk MDS or sAML. There was no other potential
baseline and transplantation-related factor affecting the
cumulative incidence of NRM (P > .100) (Supplementary
Table S1).
Overall and DFS
At amedian of 44.8 (95%CI, 40.2 to 49.4)months follow-up
for survivors, 29 (48.3%) patients survived and 26 (43.3%)
remained alive without relapse. The estimated OS and DFS
rates at 4 years for all patients were 46.8% (95% CI, 33.2% to
59.3%) and 41.9% (95% CI, 28.9% to 54.3%), respectively. There
were signiﬁcant differences in OS (72.2% [95% CI, 40.8% to
88.9%] versus 38.5% [95%CI, 24.3% to 52.5%]; P¼ .023) andDFS
(75.0% [95% CI, 46.3% to 89.8%] versus 28.6% [95% CI, 15.2% to
43.6%]; P ¼ .008) at 4 years between the patients with lower-
risk MDS and higher-risk MDS or sAML at peak (Figure 2C,D).
In univariate analysis, the cytogenetic risk at transplantation
(poor versus good/intermediate; P ¼ .057 and P ¼ .034,
respectively) were additional potential factors predicting
the OS and DFS rates (Supplementary Table S1). Other
baseline clinical or transplantation-related factors did not
affect OS andDFS rates (P> .100) (Supplementary Table S1). In
multivariate analysis, disease risk at peak (HR, 4.44; 95% CI,
1.14 to 17.34; P¼ .032)was the only signiﬁcant factor affecting
the DFS rate, whereas therewas no signiﬁcant factor affecting
the OS rate (Table 3).
DISCUSSION
Up to now, there are scare reports on outcomes of
haploidentical SCT in patients with MDS or sAML [9,12].
Herein, we analyzed the long-term outcomes of 60
consecutive patients with MDS or sAML who received TCR
haploidentical SCT with PB stem cells using RIC regimens.
Previous studies that analyzed the outcomes of patients
who received allogeneic SCT using conventional donors
reported that their cumulative incidences of relapse at
3 years were 23% to 41% [30-32]. Although direct com-
parison was difﬁcult because of discrepancies in patient
populations, the incidence of relapse in our cohort (34.8%
at 4 years) was similar to that of previous studies.
This suggests that the antileukemic effect of our TCR
haploidentical SCT is at least not inferior to that ofnts, (B) CD8þ T cell counts, and (C) CD4þ T cell counts. Error bars indicate
Figure 2. Major transplantation outcomes of all patients and according to the disease risk at peak. (A) relapse, (B) NRM, (C) overall survival, and (D) DFS.
S.-H. Shin et al. / Biol Blood Marrow Transplant 21 (2015) 342e349346allogeneic SCT using conventional donors, although the
high incidence of relapse still remains the main cause of
treatment failure, especially in patients with higher-risk
MDS or sAML. In addition, the cumulative incidence of
NRM in our cohort at 4 years was only 23.3%, which was
lower compared with the aforementioned studies (32% to
44% at 3 years), although the increased risk of toxicities
after haploidentical SCT due to the bidirectional barrier of
HLA incompatibilities was predicted. This suggests that
rapid engraftment and early immune reconstitution with
an effective GVHD prophylaxis contributed to the relatively
low incidence of NRM. Consequently, the estimated OS and
DFS rates of our patients at 4 years (46.8% and 41.9% at 4
years, respectively) were acceptable, which showed thatTable 3
Multivariate Analyses of Factors Affecting Major Transplantation Outcomes
Factors Relapse P NRM
HR (95% CI) HR (95% CI
Age at transplantation
48 yr versus <48 yr 1.76 (.86-3.63) .124
Disease risk at peak
Hr-MDS/sAML versus Lr-MDS 5.69 (1.45-22.29) .013
Cytogenetic risk at transplantation
Poor versus good/intermediate
Acute GVHD grade II-IV
No versus yes 2.44 (.53-9.43) .272 .26 (.05-1.5
Chronic GVHD
No versus yes 2.78 (1.03-7.51) .043 .33 (.07-1.5
Hr-MDS indicates higher-risk myelodysplastic syndrome; Lr-MDS, lower-risk MDSour TCR haploidentical SCT may be a feasible option for
patients with MDS or sAML.
Rapid repopulating lymphocytes after allogeneic SCT
plays an essential role in preventing fatal infectious
complications and reducing the incidence of early relapse
by eradiating residual tumor cells [33,34]. Several studies
have reported that higher survival rates by early immune
reconstitution were observed in TCR haploidentical SCT
compared with T celledepleted haploidentical SCT
[8,13,35]. Chang et al. showed that delayed recovery of the T
cell subset was observed in the ﬁrst 3 months in TCR hap-
loidentical SCT compared with allogeneic SCT from MSD,
using MAC regimens, but did not result in inferior outcomes
except higher incidence of CMV reactivation [36]. ComparedP OS P DFS P
) HR (95% CI) HR (95% CI)
3.83 (.96-15.21) .057 4.44 (1.14-17.34) .032
1.17 (.73-4.01) .218 1.81 (.83-3.94) .138
0) .132 1.10 (.34-3.59) .871 1.26 (.41-3.92) .690
3) .158 1.50 (.57-3.96) .410 1.29 (.53-3.13) .568
.
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cells in our cohort were faster, which might have resulted
from using RIC regimen [37-39]. In accordance with these
results, only 5 (8.3%) patients died of infectious complica-
tions among 14 patients who experienced NRM in our
study. We also demonstrated that NK cells and CD8þ T cells
recovered early after transplantation and substantial re-
covery of CD4þ T cells was also observed 6 months after
transplantation. Those beneﬁcial effects on survival rates of
an early immune reconstitution were possible because
GVHD, with an incidence that may be increased by using
TCR grafts, was effectively controlled. In addition to the
prophylactic effect of rabbit ATG, which induced in vivo T
cell depletion, calcineurin inhibitors, and methotrexate, we
assume the RIC regimen also may contribute to the control
of GVHD. It has generally been accepted that the RIC
regimen could be associated with less tissue damage and
the production of tumor necrosis factor-a and interleukin-6,
which are involved in the pathogenesis of GVHD [40,41].
This hypothesis is supported by a recent comparative study
comparing MAC and RIC allogeneic SCT from MSD, which
showed a lower incidence of GVHD in the RIC group [42]. In
addition, several investigators comparing the outcomes of
MAC and RIC allogeneic SCT from URD showed that the
negative impact of HLA disparity on graft failure and GVHD
was lower in the latter [43,44]. Regarding this issue, Ogawa
et al. reported that most patients (96.2%) achieved rapid
sustained engraftment and their incidences of acute GVHD
grade II to IV and extensive chronic GVHD were only 20.0%
and 25.5%, respectively, after haploidentical SCT using a RIC
regimen consisting of ﬂudarabine/busulfan with rabbit ATG
[11]. Our previous analysis on haploidentical SCT using a
similar RIC regimen in 83 patients with acute leukemia and
MDS also reported that no primary graft failure was
observed and the incidences of acute GVHD grade II to IV
and chronic GVHDwere only 20% and 34%, respectively [12].
The incidences of acute GVHD grade II to IV and chronic
GVHD in these studies were considerably lower compared
with those (60% and 56%, respectively) of haploidentical SCT
after a MAC regimen for the patients with MDS or sAML by
Chen et al. [9]. Collectively, all of these studies suggest the
RIC regimen may play some potential role in overcoming
the high bidirectional barrier of haploidentical SCT.
Because of unacceptable toxicities in the early develop-
ment period, haploidentical SCT had been considered a
therapeutic option in patients with very aggressive hema-
tologic malignancies and lacking HLA-matched conventional
donors. However, recent improvements in controlling graft
failure and GVHD made it a considerable option for patients
with less aggressive disease, even with severe aplastic ane-
mia [45]. For patients with lower-risk MDS, the selection of
transplantation strategies to minimize toxicities is most
important because their disease risk predicts a low incidence
of relapse [19]. Although decision analyses showed that
the patients with lower-risk MDS could achieve maximal
life expectancy when allogeneic SCT was delayed as far
as possible [46,47], an early allogeneic SCT should be
considered if they have speciﬁc PPF because of their high risk
of life-threatening conditions or transformation to sAML
[14]. Our cohort included 16 patients with lower-risk MDS
with at least 1 PPF, and 12 of these patients (75.0%) survived
without relapse at the last follow-up, although a substantial
proportion of patients experienced an HMT failure, sug-
gesting a poor prognosis [48,49]. Consequently, theirestimated DFS rate at 4 years was 75.0%; the cumulative
incidence of relapse and NRM at 4 years was 6.2% and 18.8%,
respectively.
To the best of our knowledge, our study is the ﬁrst report
with a long-term follow-up duration, suggesting the feasi-
bility of haploidentical SCT in patients with lower-risk MDS
with PPF, even there is a small number of patients. Conse-
quently, patients with lower-risk MDS with signiﬁcant
cytopenia with recurrent infection or bleeding, RBC trans-
fusion dependency not responding to erythroid stimulating
agents, and/or HMT failure may be the candidates of hap-
loidentical SCT, considering the high survival rateswith a low
incidence of relapse and NRM in our study.
As the high incidences of both relapse and NRM were
prevalent problems in allogeneic SCT from HLA-matched
conventional donors for patients with higher-risk MDS
or sAML [30,50], the cumulative incidences of relapse and
NRM at 4 years (46.4% and 25.0%, respectively) in our cohort
were relatively high. Chen et al. reported a lower incidence
of relapse at 2 years (19.3%), compared with our cohort,
by conducting haploidentical SCT using MAC regimen with
G-CSFeprimed BM and PBSC grafts in patients with
advanced MDS or sAML [9], although it did not reﬂect late
relapses because the median follow-up duration of their
cohort was relatively short (17months). However, their more
intensiﬁed conditioning regimen might have contributed to
the lower incidence of relapse. Therefore, 1 possible
approach to improve the outcome for patients with higher-
risk MDS and sAML may be intensifying the conditioning
regimen. Our own subgroup analysis in patients with higher-
risk MDS also showed that moderate intensiﬁcation of con-
ditioning regimen by adding 800cGy TBI resulted in higher
survival rates without increased incidence of NRM (data not
shown), although further studies are needed to conﬁrm this
result. Another option may be an early adoption of hap-
loidentical donors in patients requiring an urgent trans-
plantation rather than repeated and prolonged searches of
matched conventional donors before those experience HMT
failure or acquire additional cytogenetic aberrations [51,52].
On the other hand, chronic GVHD was a signiﬁcant factor
that affected the incidence of relapse in our analysis.
Although many reports showed the graft-versus-leukemia
effect of chronic GVHD in allogeneic SCT from conventional
donors [53], there is no report regarding haploidentical
SCT [5-8,11-13,35]. Therefore, further studies are needed
to conﬁrm this effect in haploidentical SCT, considering
our result was derived from a small number of patients.
In addition, patients in our cohort had a median age of
48 years, which was relatively young, considering most
patients who are diagnosed with MDS were 65 years old
[54,55]. This limitation of our study evokes a concern
regarding the applicability of our data to elderly patients,
although recent studies that showed their outcomes for RIC
allogeneic SCT using conventional donors were feasible
[47,56,57]. To address this issue, additional studies are
needed to determine whether our TCR haploidentical SCT
using RIC regimens are also effective for them.
Even with improved outcomes of haploidentical SCT,
MSD is the best donor source in the allogeneic SCT for pa-
tients with MDS or sAML, considering a recent large registry
analysis that showed that allogeneic SCT from MSD
provided signiﬁcant better survival rates compared with
those from HLA-matched URD [31]. However, the results of
our current study suggest that TCR haploidentical SCT using
S.-H. Shin et al. / Biol Blood Marrow Transplant 21 (2015) 342e349348RIC regimen consisting of ﬂudarabine/busulfan  TBI with
rabbit ATG may be a feasible option for at least a selected
subgroup of patients with MDS or sAML. Of course, the
limitations of our retrospective analysis because of the
small numbers of patients should be validated in well-
designed prospective studies including larger numbers of
patients. In addition, new transplantation strategies
including the use of risk-stratiﬁed modiﬁcation of condi-
tioning intensity, may further improve the outcomes of
patients with MDS or sAML.ACKNOWLEDGMENTS
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